Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.
A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.
Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS. Natalizumab, which is given every four weeks as an infusion or injection, has ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
A new trial will test whether a jab to protect against a common virus found in almost all people with multiple sclerosis (MS) could treat the condition. Scientists believe that targeting the ...
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results